European guidelines for topical photodynamic therapy part 2: Emerging indications - Field cancerization, photorejuvenation and inflammatory/infective dermatoses

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 6, 2013, Pages 672-679

  Morton, C A ^a   Szeimies, R M ^b   Sidoroff, A ^c   Braathen, L R ^d  

^a Stirling Royal Infirmary   (United Kingdom)

^b Knappschaftskrankenhaus Recklinghausen   (Germany)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d Department of Dermatology ^*  (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACNE; COST EFFECTIVENESS ANALYSIS; CUTANEOUS T CELL LYMPHOMA; GRAFT RECIPIENT; HYPERPIGMENTATION; INFECTIVE DERMATOSIS; INFLAMMATORY DERMATOSIS; PAGET SKIN DISEASE; PHOTODYNAMIC THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REJUVENATION; REVIEW; SKIN DISEASE; SKIN LEISHMANIASIS; TREATMENT INDICATION; WRINKLE;

COSMETIC TECHNIQUES; DERMATITIS; HUMANS; PHOTOCHEMOTHERAPY; REJUVENATION; SKIN DISEASES, INFECTIOUS; SKIN NEOPLASMS;

EID: 84877629937     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12026     Document Type: Review

References (93)

1. Morton CA, Szeimies RM, Sidoroff A, Braathen LR,. European guidelines for photodynamic therapy part 1: current indications. J Eur Acad Dermatol Venereol 2013; 27: 536-544.
2. Braathen Lasse R, Szeimies Rolf M, Basset Seguin N, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. J Am Acad Dermatol 2007; 56: 125-143.
3. Morton CA, McKenna KE, Rhodes LE,. Guidelines for topical photodynamic therapy. Br J Dermatol 2008; 159: 1245-1266.
4. Oseroff A,. PDT as a cytotoxic agent and biological response modifier: implications for cancer prevention and treatment in immunosuppressed and immunocompetent patients. J Invest Dermatol 2006; 126: 542-544.
5. Jang MS, Doh KS, Kang JS, et al. A comparative split-face study of photodynamic therapy with indocyanine green and indole-3-acetic acid for the treatment of acne vulgaris. Br J Dermatol 2011; 165: 1095-1100.
6. Wiegell S, Wulf HC,. Photodynamic therapy of acne vulgaris using 5-aminolevulinic acid versus methyl aminolevulinate. J Am Acad Dermatol 2006; 54: 647-651.
7. Stender I-M, Borgbjerg F, Molke Villumsen J, Lock-Andersen J, Wulf H-C,. Pain induced by photodynamic therapy of warts. Photodermatol Photoimmunol Photomed 2006; 22: 304-309.
8. Dragieva G, Prinz BM, Hafner J, et al. A randomised controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. Br J Dermatol 2004; 151: 196-200.
9. Piaserico S, Belloni Fortina A, Rigotti P, et al. Topical photodynamic therapy of actinic keratosis in renal transplant patients. Transplant Proc 2007; 39: 1847-1850.
10. Schleier P, Hyckel P, Berndt A, et al. Photodynamic therapy of virus-associated epithelial tumours of the face in organ transplant recipients. J Cancer Res Clin Oncol 2004; 130: 279-284.
11. Dragieva G, Hafner J, Dummer R, et al. Topical photodynamic therapy in the treatment of actinic keratoses and Bowen's disease in transplant recipients. Transplantation 2004; 77: 115-121.
12. Perrett CM, McGregor JM, Warwick J, et al. Treatment of post-transplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil and topical photodynamic therapy. Br J Dermatol 2007; 156: 320-328.
13. Wulf HC, Pavel S, Stender I, Bakker-Wensveen CAHB,. Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. Acta Derm Venereol 2006; 86: 25-28.
14. Wennberg AM, Stenquist B, Stockfleth E, et al. Photodynamic therapy with methyl aminolevulinate for prevention of new lesions in transplant recipients: a randomized study. Transplantation 2008; 86: 423-429.
15. De Graaf YGL, Kennedy C, Wolterbeek R, et al. Photodynamic therapy does not prevent cutaneous squamous-cell carcinoma in organ-transplant recipients: results of a randomized-controlled trial. J Invest Dermatol 2006; 126: 569-574.
16. Willey A, Mehta S, Lee PK,. Reduction in incidence of squamous cell carcinoma in solid organ transplant recipients treated by cyclic Photodynamic therapy. Dermatol Surg 2010; 36: 652-658.
17. Braathen L., Morton C., Basset-Seguin N, et al.,. Photodynamic therapy for skin field cancerization: an international consensus. International Society for Photodynamic Therapy in Dermatology. J Eur Acad Dermatol Venereol 2012; 26: 1063-1066.
18. Basset-Seguin N, Baumann Conzett K, Gerritsen MJP, et al.,. Photodynamic therapy for actinic keratoses in organ transplant recipients. J Eur Acad Dermatol Venereol 2012; DOI: 10.1111/J.1468-3083.2011.04356.
19. Apalla Z, Sotiriou E, Chovarda E, Lefaki I, Devliotou-Panagiotidou D, Ioannides D,. Skin cancer: preventive photodynamic therapy in patients with face and scalp cancerization. A randomized placebo-controlled study. Br J Dermatol 2010; 162: 171-175.
20. Bagazgoitia L, Cuevas Santos J, Juarranz A, Jaen P,. Photodynamic therapy reduces the histologic features of actinic damage and the expression of early oncogenic markers. Br J Dermatol 2011; 165: 144-145.
21. Szeimies RM, Torezan L, Niwa A, et al.,. Clinical, histopathological and immunohistochemical assessment of human skin field cancerization before and after photodynamic therapy. Br J Dermatol 2012; 167: 150-159 DOI: 10.1111/j.1365-2133.2012.10887.x
22. Zane C, Venturini M, Sala R, Calzavara-Pinton P,. Photodynamic therapy with methylaminolevulinate as a valuable treatment option for unilesional cutaneous T-cell lymphoma. Photodermatol Photoimmunol Photomed 2006; 22: 254-258.
23. Edstrom DW, Porwit A, Ros AM,. Photodynamic therapy with topical 5-aminolevulinic acid for mycosis fungoides: clinical and histological response. Acta Derm Venereol 2001; 81: 184-188.
24. Debu A, Girard C, Kluger N, Guillot B, Dereure O,. Topical methyl aminolaevulinate photodynamic therapy in erosive facial mycosis fungoides. Br J Dermatol 2010; 163: 884-885.
25. Mori M, Campolmi P, Mavilia L, et al. Topical photodynamic therapy for primary cutaneous B-cell lymphoma: a pilot study. J Am Acad Dermatol 2006; 54: 524-526.
26. Shieh S, Dee AS, Cheney RT, et al. Photodynamic therapy for the treatment of extramammary Paget's disease. Br J Dermatol 2002; 146: 1000-1005.
27. Mikasa K, Watananabe D, Kondo C, et al. 5-Aminolevulinic acid-based photodynamic therapy for the treatment of two patients with extramammary Paget's disease. J Dermatol 2005; 32: 97-101.
28. Rapagliesi F, Fontanelli R, Rossi G, et al. Photodynamic therapy using a methyl ester of 5-aminolaevulinic acid in recurrent Paget's disease of the vulva: a pilot study. Gynecol Oncol 2006; 103: 581-586.
29. Zawislak AA, McCarron PA, McCluggage WG, et al. Successful photodynamic therapy of vulval Paget's disease using a novel patch-based delivery system containing 5-aminolevulinic acid. Br J Obstet Gynaecol 2004; 111: 1143-1145.
30. Sakamoto FH, Lopes JD, Anderson RR,. Photodynamic therapy for acne vulgaris: a critical review from basics to clinical practice Part 1 Acne: when and why consider photodynamic therapy? J Am Acad Dermatol 2010; 63: 183-193.
31. Ramstad S, Futsaether CM, Johnsson A,. Porphyrin sensitization and intracellular calcium changes in the prokaryote, propionibacterium acnes. J Photochem Photobiol, B 1997; 40: 141-148.
32. Sakamoto FH, Torezan L, Anderson RR,. Photodynamic therapy for acne vulgaris: a critical review from basics to clinical practice Part 2 Understanding parameters for acne treatment with photodynamic therapy. J Am Acad Dermatol 2010; 63: 195-211.
33. Nester MS, Gold MH, Kauvar ANB, et al. The use of photodynamic therapy in Dermatology: results of a consensus conference. J Drugs Dermatol 2006; 5: 140-154.
34. Wiegell SR, Wulf HC,. Photodynamic therapy of acne vulgaris using methyl aminolaevulinate: a blinded, randomized, controlled trial. Br J Dermatol 2006; 154: 969-976.
35. Horfelt C, Funk J, Frohm-Nilsson M, et al. Topical methyl aminolaevulinate photodynamic therapy for treatment of facial acne vulgaris: results of a randomized, controlled study. Br J Dermatol 2006; 155: 608-613.
36. Mavilia L, Malara G, Moretti G, et al. Photodynamic therapy of acne using methyl aminolevulinate diluted to 4% together with low doses of red light. Br J Dermatol 2007; 157: 810-811.
37. de Leeuw J, van der Beek N, Bjerring P, Neumann HAM,. Photodynamic therapy of acne vulgaris using 5-aminolevulinic acid 0.5% liposomal spray and intense pulsed light in combination with topical keratolytic agents. J Eur Acad Dermatol Venereol 2010; 24: 460-469.
38. Horn M, Wolf P,. Topical methyl aminolevulinate photodynamic therapy for the treatment of folliculitis. Photodermatol Photoimmunol Photomed 2007; 23: 145-147.
39. Horio T, Horio O, Miyauchi-Hashimoto H, et al. Photodynamic therapy of sebaceous hyperplasia with topical 5-aminolaevulinic acid and slide projector. Br J Dermatol 2003; 148: 1274-1276.
40. Alster TS, Tanzi EL,. Photodynamic therapy with topical aminolevulinic acid and pulsed dye laser irradiation for sebaceous hyperplasia. J Drugs Dermatol 2003; 2: 501-504.
41. Gold MH, Bradshaw VL, Boring MM, et al. Treatment of sebaceous gland hyperplasia by photodynamic therapy with 5-aminolevulinic acid and a blue light source or intense pulsed light source. J Drugs Dermatol 2004; 6 (Suppl): S6-S9.
42. Perrett CM, McGregor J, Barlow RJ, et al. Topical photodynamic therapy with methyl aminolevulinate to treat sebaceous hyperplasia in an organ transplant recipient. Arch Dermatol 2006; 142: 781-782.
43. Gold MH, Bridges NM, Bradshaw VL, Boring M,. ALA-PDT and blue light therapy for hidradenitis suppurativa. J Drugs Dermatol 2004; 3: S32-S35.
44. Strauss RM, Pollock B, Stables GI, et al. Photodynamic therapy using aminolaevulinic acid does not lead to clinical improvement in hidradenitis suppurativa. Br J Dermatol 2005; 152: 803-804.
45. Bryld LE, Jemec GBE,. Photodynamic therapy in a series of rosacea patients. J Eur Acad Dermatol Venereol 2007; 21: 1199-1202.
46. Togsverd-Bo K, Wiegell SR, Wulf HC, Haedersdal M,. Short and limited effect of long-pulsed dye laser alone and in combination with photodynamic therapy for inflammatory rosacea. J Eur Acad Dermatol Venereol 2008; 23: 200-201.
47. Stender I M, Na R, Fogh H, Gluud C, Wulf H C,. Photodynamic therapy with 5-aminolaevulinic acid or placebo for recalcitrant foot and hand warts: randomised double-blind trial. Lancet 2000; 355: 963-966.
48. Stender I.M, Lock-Andersen J, Wulf HC,. Recalcitrant hand and foot warts successfully treated with photodynamic therapy with topical 5-aminolaevulinic acid: a pilot study. Clin Exp Dermatol 1999; 24: 154-159.
49. Smucler R, Jatsova E,. Comparative study of aminolevulinic acid photodynamic therapy plus pulsed dye laser versus pulsed dye laser alone in treatment of viral warts. Photomed Laser Surg 2005; 31: 51-53.
50. Mizuki D, Kaneko T, Hanada K,. Successful treatment of topical photodynamic therapy using 5-aminolevulinic acid for plane warts. Br J Dermatol 2003; 149: 1087-1088.
51. Lu YG, Wu JJ, He Y, Yang HZ, Yang YD,. Efficacy of topical aminolaevulinic acid photodynamic therapy for the treatment of verruca planae. Photomed Laser Surg 2010; 28: 651-653.
52. Schroeter CA, Kaas L, Waterval JJ, Bos PM, Neumann HAM,. Successful treatment of periingual warts using photodynamic therapy: a pilot study. J Eur Acad Dermatol Venereol 2007; 21: 1170-1174.
53. Chiong W-S, Kang GYM,. Dramatic clearance of a recalcitrant acral wart using methyl aminolevulinate-red light photodynamic therapy. Photodermatol Photoimmunol Photomed 2009; 25: 225-226.
54. Fehr MK, Hornung P, Schwarz VA, et al. Photodynamic therapy of vulvar and vaginal condylomata and intraepithelial neoplasia using topical 5-aminolaevulinic acid. Lasers Surg Med 2002; 30: 273-279.
55. Stefanaki IM, Georgiou S, Themelis GC, et al. In vivo fluorescence kinetics and photodynamic therapy in condylomata acuminata. Br J Dermatol 2003; 149: 972-976.
56. Wang XL, Wang HW, Wang HS, et al. Topical 5-aminolaevulinic acid-photodynamic therapy for the treatment of urethral condylomata acuminata. Br J Dermatol 2004; 151: 880-885.
57. Chen K, Chang BZ, Ju M, et al. Comparative study of photodynamic therapy vs. CO2 laser vaporization in treatment of condylomata acuminate, a randomized clinical trial. Br J Dermatol 2007; 156: 516-520.
58. Liang J, Lu XN, Tang H, Zhang Z, Fan J, Xu JH,. Evaluation of photodynamic therapy using topical aminolaevulinic acid hydrochloride in the treatment of condyloma acuminate: a comparative, randomized clinical trial. Photodermatol Photoimmunol Photomed 2009; 25: 293-297.
59. Szeimies RM, Schleyer V, Moll I, et al. Adjuvant photodynamic therapy does not prevent recurrence of condylomata acuminata after carbon dioxide laser ablation-A phase III, prospective, randomized, bicentric, double-blind study. Dermatol Surg 2009; 35: 757-764.
60. van der Snoek EM, Robinson DJ, van Hellemond JJ, Neumann HAM,. A review of photodynamic therapy in cutaneous leishmaniasis. J Eur Acad Dermatol Venereol 2008; 22: 918-922.
61. Enk CD, Fritsch C, Jonas F, et al. Treatment of cutaneous leishmaniasis with photodynamic therapy. Arch Dermatol 2003; 139: 432-434.
62. Asilian A, Davami M,. Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebo-controlled, randomized clinical trial. Clin Exp Dermatol 2006; 31: 634-637.
63. Akilov OE, Kosaka S, O'Riordan K, Hasan T,. A mechanistic study of delta-aminolevulinic acid-based photodynamic therapy for cutaneous leishmaniasis. J Invest Dermatol 2007; 127: 1546-1549.
64. Abok K, Cadelas E, Brunk U,. An experimental model system for leishmaniasis. Effects of porphyrin-compounds and menadione on leishmania parasites engulfed by cultured macrophages. APMIS 1998; 96: 543-551.
65. Kohl E, Torezan LAR, Landthaler M, Szeimies RM,. Aesthetic effects of topical photodynamic therapy. J Eur Acad Dermatol Venereol 2010; 24: 1261-1269.
66. Dover J, Bhatia AC, Stewart B, Arndt KA,. Topical 5-aminolevulinic acid combined with intense pulsed light in the treatment of photoaging. Arch Dermatol 2005; 141: 1247-1252.
67. Gold M, Bradshaw VL, Boring MM, et al. Split-face comparison of photodynamic therapy with 5-aminolevulinic acid and intense pulsed light versus intense pulsed light alone for photodamage. Dermatol Surg 2006; 32: 795-801.
68. Key DJ,. Aminolaevulinic acid-pulsed dye laser photodynamic therapy for the treatment of photoaging. Cosmet Dermatol 2005; 18: 31-36.
69. Ruiz-Rodriguez R, Lopez L, Candelas D, Pedraz J,. Photorejuvenation using topical 5-methyl aminolevulinate and red light. J Drugs Dermatol 2008; 7: 633-637.
70. Ruiz-Rodriguez R, Lopez L, Candelas D, Zelickson B,. Enhanced efficacy photodynamic therapy after fractional resurfacing: fractional photodynamic rejuvenation. J Drugs Dermatol 2007; 6: 818-820.
71. Sanclemente G, Medina L, Villa J-F, Barrera L-M, Garcia H-I,. A prospective split-face double-blind randomized placebo-controlled trial to assess the efficacy of methyl aminolevulinate + red-light in patients with facial photodamage. J Eur Acad Dermatol Venereol 2011; 25: 49-58.
72. Karrer S, Abels C, Landthaler M, Szeimies R-M,. Topical photodynamic therapy for localized scleroderma. Acta Derm Venereol 2000; 80: 26-27.
73. Karrer S, Bosserhoff AK, Weiderer P, et al. Influence of 5-amino-levulinic acid and red light on collagen metabolism of human dermal fibroblasts. J Invest Dermatol 2003; 120: 325-331.
74. Zawislak AA, McCluggage WG, Donnelly RF, et al. Response of vulval lichen sclerosus and squamous hyperplasia to photodynamic treatment using sustained topical delivery of aminolaevulinic acid from a novel bioadhesive patch system. Photodermatol Photoimmunol Photomed 2009; 25: 111-113.
75. Hillemanns P, Untch M, Prove F, et al. Photodynamic therapy of vulvar lichen sclerosus with 5-aminolaevulinic acid. Obstet Gynecol 1999; 93: 71-74.
76. Exadaktylou D, Kurwa HA, Calonje E, Barlow RJ,. Treatment of Darier's disease with photodynamic therapy. Br J Dermatol 2003; 149: 606-610.
77. Richey DF, Hopson B,. Photodynamic therapy for perioral dermatitis. J Drugs Dermatol 2006; 5: 12-16.
78. Escudero A, Nagore E, Sevila A, et al. Chronic x-ray dermatitis treated by topical 5-aminolaevulinic acid photodynamic therapy. Br J Dermatol 2002; 147: 394-395.
79. Gilaberte Y, Frias MP, Perez-Lorenz JB,. Chondrodermatitis nodularis helicis successfully treated with photodynamic therapy. Arch Dermatol 2010; 146: 1080-1082.
80. Moiin A,. Photodynamic therapy for molluscum contagiosum infection in HIV-co-infected patients: review of 6 patients. J Drugs Dermatol 2003; 2: 637-639.
81. Calzavara-Pinton PG, Venturini M, Capezzera R, et al. Photodynamic therapy of interdigital mycoses of the feet with topical application of 5-aminolevulinic acid. Photodermatol Photoimmunol Photomed 2004; 20: 144-147.
82. Sotiriou E, Koussidou T, Patsatsi A, Apalla Z, Ionnides D,. 5-aminolevulinic acid-photodynamic therapy treatment for dermatophyte tinea pedis of interdigitate type: a small clinical study. J Eur Acad Dermatol Venereol 2009; 23: 203-204.
83. Sotiriou E, Panagiotidou D, Ionnides D,. 5-aminolevulinic acid-photodynamic therapy treatment for tinea cruris caused by Trychophyton rubrum: report of 10 cases. J Eur Acad Dermatol Venereol 2009; 23: 341-342.
84. Schleyer V, Radakovic-Fijan S, Kerrer S, et al. Disappointing results and low tolerability of photodynamic therapy with topical 5-aminolaevulinic acid in psoriasis. A randomized, double-blind phase I/II study. J Eur Acad Dermatol Venereol 2006; 20: 823-828.
85. Beattie PE, Dawe RS, Ferguson J, Ibbotson SH,. Lack of efficacy and tolerability of topical PDT for psoriasis in comparison with narrowband UVB phototherapy. Clin Exp Dermatol 2004; 29: 560-562.
86. Radakovic-Fijan S, Blecha-Thalhammer U, Schleyer V, et al. Topical aminolaevulinic acid-based photodynamic therapy as a treatment option for psoriasis? Results of a randomized, observer-blinded study Br J Dermatol 2005; 152: 279-283.
87. Campbell SM, Tyrrell J, Marshall R, Curnow A,. Effect of MAL-photodynamic therapy on hypertrophic scarring. Photodiagn Photodyn Ther 2010; 7: 183-188.
88. Sakamoto F, Izikson L, Tannous Z, Zurakowski D, Anderson RR,. Surgical scar remodelling after photodynamic therapy using aminolaevulinic acid or its methylester: a retrospective, blinded study of patients with field cancerization. Br J Dermatol 2012; 166: 413-416.
89. Caekelbergh K, Annemans L, Lambert J, Roelands R,. Economic evaluation of methyl aminolevulinate photodynamic therapy in the management of actinic keratoses and basal cell carcinoma. Br J Dermatol 2006; 155: 784-790.
90. Annemans L, Caekelbergh K, Roelandts R, et al. Real-life practice study of the clinical outcome and cost-effectiveness of photodynamic therapy using methyl aminolevulinate (MAL-PDT) in the management of actinic keratosis and basal cell carcinoma. Euro J Dermatol 2008; 18: 539-546.
91. Aguilar M, De Troya M, Martin L, Benítez N, González M,. A cost analysis of photodynamic therapy with methyl aminolevulinate and imiquimod compared with conventional surgery for the treatment of superficial basal cell carcinoma and Bowen's disease of the lower extremities. J Eur Acad Dermatol Venereol 2010; 24: 1431-1436.
92. Wilson ECF,. Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model. Pharmacoeconomics 2010; 28: 1055-1064.
93. Muston D, Downs A, Rives V,. An economic evaluation of topical treatments for actinic keratosis. J Dermatolog Treat 2009; 20: 1-10.